Revenue ₹1,743 Cr (+22% YoY)
0 met · 0 close · 13 missed across 13 tracked promises
View all executive profiles for Gland Pharma LimitedGland Pharma reported a strong Q4 FY26 with consolidated revenue of INR 17,428 million (+22% YoY) and adjusted EBITDA...
0% promises delivered
Based on 13 tracked promises across 12 quarters
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q4 FY26
15 May 2026
Revenue ₹1,743 Cr (+22% YoY)
Gland Pharma reported a strong Q4 FY26 with consolidated revenue of INR 17,428 million (+22% YoY) and adjusted EBITDA margin of 30% (+500bps YoY), driven by robust CDM...
bullish
high
1 missed
Read full analysis →
Q3 FY26
15 Jan 2026
Revenue ₹1,695 Cr (+22% YoY)
Gland Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 1,695.4 crore (+22% YoY) and adjusted EBITDA of INR 449 crore (+25% YoY), driven by broad-base...
bullish
high
1 missed
Read full analysis →
Q2 FY26
06 Nov 2025
Revenue ₹1,487 Cr (+6% YoY)
Gland Pharma reported a strong Q2 FY26 with consolidated revenue of INR 14,869 million, up 6% YoY, and EBITDA of INR 3,139 million (21% margin).
bullish
high
Scorecard starts after historical backfill
Read full analysis →
Q1 FY26
01 Aug 2025
Revenue ₹1,506 Cr (+7% YoY)
Gland Pharma reported a solid Q1 FY26 with consolidated revenue of INR 1,506 crore (+7% YoY) and EBITDA of INR 368 crore (+39% YoY), driving margins to 24% (up 500bps...
bullish
high
1 missed
Read full analysis →
Q4 FY25
15 May 2025
Revenue ₹1,425 Cr
Gland Pharma's Q4 FY25 consolidated revenue was INR 1,424.9 crore with EBITDA of INR 347.5 crore (24% margin, +100bps YoY).
neutral
medium
1 missed
Read full analysis →
Q3 FY25
23 Jan 2025
Revenue ₹1,384 Cr
Gland Pharma's Q3 FY25 consolidated revenue was INR 1,384 crore, with EBITDA margin improving 100 bps YoY to 26%.
neutral
medium
2 missed
Read full analysis →
Q2 FY25
30 Oct 2024
Revenue ₹1,406 Cr (+2% YoY)
Gland Pharma's Q2 FY25 consolidated revenue grew 2% YoY to INR 1,406 crore, with base business up 5% to INR 1,066 crore.
neutral
medium
Scorecard starts after historical backfill
Read full analysis →
Q1 FY25
14 Aug 2024
Revenue ₹1,407 Cr (+16% YoY)
Gland Pharma reported consolidated revenue of INR 14,070 million (+16% YoY), driven by 14% growth in the base business and Cenexi contribution.
neutral
medium
1 missed
Read full analysis →
Q4 FY24
14 May 2024
Revenue ₹1,537 Cr (+19% YoY)
Gland Pharma reported a strong Q4 FY24 with consolidated revenue of INR 16,375 million (+19% YoY) and EBITDA of INR 3,587 million (+113% YoY), driven by a robust recov...
bullish
high
Scorecard starts after historical backfill
Read full analysis →
Q3 FY24
12 Feb 2024
Revenue ₹1,545 Cr (+65% YoY)
Gland Pharma reported consolidated revenue of INR 1,545 crore in Q3 FY24, up 65% YoY, driven by the Cenexi acquisition and strong US base business growth of 17% YoY.
neutral
medium
3 missed
Read full analysis →
Q2 FY24
09 Nov 2023
Revenue ₹1,373 Cr (+32% YoY)
Gland Pharma reported consolidated revenue of INR 1,373.4 crore in Q2 FY24, up 32% YoY, driven by Cenexi acquisition and US market recovery.
neutral
medium
3 missed
Read full analysis →
Q1 FY24
09 Aug 2023
Revenue ₹1,209 Cr (+41% YoY)
Gland Pharma reported consolidated revenue of INR 1,209 crore for Q1 FY24, up 41% YoY, driven by the Cenexi acquisition (37% contribution) and 4% base business growth.
neutral
medium
Scorecard starts after historical backfill
Read full analysis →